A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease
Not Applicable
Completed
- Conditions
- Alzheimer's diseaseNervous System Diseases
- Registration Number
- ISRCTN96337233
- Lead Sponsor
- West Midlands NHS Research & Development Executive (UK)
- Brief Summary
2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15220031 2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18068522
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 310
Inclusion Criteria
1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnosis of Alzheimer's disease, with or without evidence of vascular dementia
2. Mild to moderate Alzheimer's disease (Mini Mental State Examination [MMSE] score 10 - 26)
3. No definite contraindication to, or clear indication for, donepezil
4. Not in residential care
5. Regular carer
6. Not have already taken donepezil or any other cholinergic enhancing agent
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Cognition (assessed with the mini-mental state examination [MMSE])<br> 2. Functional ability (assessed with the Bristol activities of daily living scale [BADLS])<br><br> Patients were assessed at 12-week intervals in the first year and once each year thereafter.<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Time to formal domiciliary or institutional care<br> 2. Progress of disability<br> 3. Behavioural symptoms<br> 4. Caregiver wellbeing<br> 5. Care time<br><br> Patients were assessed at 12-week intervals in the first year and once each year thereafter.<br>